Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis

Journal of Neurology

Volumn 256, Issue 10, 2009, Pages 1771-1772

  Ismail, Azza ^a   Kemp, Julie ^a   Sharrack, Basil ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB; PLACEBO;

CLINICAL TRIAL; HISTOPATHOLOGY; HUMAN; LETTER; MELANOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 70349652532     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5200-9     Document Type: Letter

References (15)

1. B Adelman A Sandrock MA Panzara 2005 Natalizumab and progressive multifocal leukoencephalopathy N Engl J Med 353 432 433 15947083 10.1056/NEJMc055235 1:CAS:528:DC%2BD2MXms1KktL4%3D (Pubitemid 41132358)
2. R Bauer M Humphries R Fassler A Winklmeier SE Craig AK Bossehoff 2006 Regulation of integrin activity by MIA J Biol Chem 281 11669 11677 16517605 10.1074/jbc.M511367200 1:CAS:528:DC%2BD28Xjsleguro%3D (Pubitemid 43855424)
3. RJ Davenpor JR Munday 2007 Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today 12 13-14 569 10.1016/j.drudis.2007.05.001 (Pubitemid 47044874)
4. http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol-TPME. Accessed 29 April 2009
5. + T cells upon in vivo stimulation with allogeneic tumour J Immunol 159 650 663 9218580 1:CAS:528:DyaK2sXksVynurc%3D
6. N Larouche K Larouche A Be'liveau, et al. 1998 Transcriptional regulation of the alpha 4-integrin subunit gene in the metastatic spread of uveal melanoma Anticancer Res 18 5a 3539 3547 9858937 1:CAS:528:DyaK1MXntFGl
7. JT Mullen TK Vartanian MB Atkins 2008 Melanoma complicating treatment with natalizumab for multiple sclerosis N Engl J Med 358 6 647 648 18256405 10.1056/NEJMc0706103 1:CAS:528:DC%2BD1cXhs1enu78%3D
8. M Ogawa T Tsutsui JP Zou, et al. 1997 Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumour sites following administration of interleukin 12 Cancer Res 57 2216 2222 9187124 1:CAS:528:DyaK2sXjslGqs7o%3D
9. MA Panzara C Bozic AW Sandrock 2008 More on melanoma with transdifferentiation N Engl J Med 359 1 99 18596284 10.1056/NEJMc086089 1:CAS:528:DC%2BD1cXotFChtbg%3D
10. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomised placebo- controlled trial of natalizumab for relapsing multiple sclerosis N Eng J Med 354 899 910 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D (Pubitemid 43313657)
11. F Qian DL Vaux IL Weissman 1994 Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation Cell 77 3 335 347 8181055 10.1016/0092-8674(94)90149-X 1:CAS:528:DyaK2cXjt1Snsbw%3D
12. RA Rudick WH Stuart PA Calabresi, et al. 2006 Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 911 923 16510745 10.1056/NEJMoa044396 1:CAS:528:DC%2BD28XitVertLw%3D (Pubitemid 43313658)
13. O Stüve CM Marra A Bar-Or, et al. 2006 Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis Arch Neurol 63 10 1383 1387 17030653 10.1001/archneur.63.10.1383 (Pubitemid 44547548)
14. C Ulrich T Schmook MM Sachse, et al. 2004 Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients Dermatol Surg 30 622 627 15061846 10.1111/j.1524-4725.2004.30147.x
15. Y Yang PM Cardarelli K Lehnert, et al. 1998 LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides Eur J Immunol 28 3 995 1004 9541595 10.1002/(SICI)1521-4141(199803)28: 03<995::AID-IMMU995>3.0.CO;2-D 1:CAS:528:DyaK1cXhvFGit70%3D (Pubitemid 28116213)